Sr Director, US Medical Early Assets - Market Access

AstraZeneca GmbH; Wilmington (DE); On-site; USD 180,000 - 235,000; Full time

Job summary

AstraZeneca in Wilmington, DE seeks a SrDirector, US Medical Early Asset - Market Access to lead US access strategy for early assets. You will shape payer-focused value narratives, influence cross-functional teams, and ensure pricing, policy, and evidence considerations drive asset development from late discovery through Phase 2.

The role requires deep US payer knowledge, experience in HEOR, pricing, and cross-functional leadership across Clinical, Medical, Regulatory and Finance teams.

Qualifications

• Broad understanding of US payer and health-system environment.
• Strong HEOR, economic modeling, and value proposition development.

Responsibilities

• Define US payer-relevant elements of the Target Product Profile and shape differentiation claims.
• Provide US access input to clinical and RWE plans to support label, guidelines and payer coverage.
• Lead early value story development, core claims, and AMCP dossier requirements.
• Develop US pricing hypotheses, budget impact boundaries, and contracting scenarios.
• Co-create early economic models and RWE plans to support access and inform trial design.
• Assess policy landscape and channel dynamics impacting design and launch.
• Synthesize payer/IDN input and rapid tests to mitigate access hurdles.

Skills

Market access

HEOR

Pricing strategy

Stakeholder influence

Cross-functional leadership

Evidence strategy

Education

Bachelor's degree

Advanced degree

Job description

SrDirector, US Medical Early Assets - Market Access

Are you ready to turn ideas into life-changing medicines? At AstraZeneca, we are committed to addressing the unmet needs of patients worldwide through scientific innovation. Reporting directly to the Executive Director, US Medical Early Asset Team Lead, you will be part of a team focused on the development of ambitious US medical strategies for our early pipeline. Youwillinfluence across a complexglobalmatrixto ensure USpayer, health-system, policy, and affordabilityneeds are integrated intoassetdevelopmentand investment decisions.

Accountabilities

The Sr Director, US Medical Early Asset - Market Access is the strategic lead for shaping the US access and value strategy for our BBU portfolio pipeline assets from late discovery through Phase 2. The Senior Director ensures that payer, health-system, policy, pricing, and affordability considerations are incorporated early into asset development, evidence generation, and investment decisions. Serving as the senior US access voice on cross-functional asset teams, the Senior Director provides clear, evidence-based recommendations that strengthen future differentiation, reimbursement, and patient access.

Key Responsibilities

• US Value Strategy and TPP Input: Define US payer-relevant elements of the Target Product Profile (clinical endpoints, comparators, subpopulations, line of therapy) and shape differentiation claims that resonate with payers and health systems.
• Evidence and Study Design Influence: Provide US access input to clinical and RWE plans (endpoints, PROs, inclusion/exclusion, duration, head-to-heads, external controls) to support label, compendia, guideline inclusion, and payer coverage.
• Payer Value Proposition & Dossier Foundations: Lead early value story development (unmet need, clinical and economic value drivers), outline core claims, and define requirements for future AMCP dossier modules and global value dossiers.
• Early Pricing and Contracting Hypotheses: Develop US WAC/NET ranges, reference pricing considerations, budget impact boundaries, and contracting scenarios (e.g., outcomes-based, indication-based) with assumptions and risks.
• HEOR & RWE Strategy: Co-create early economic models and RWE plans (burden of illness, treatment patterns, comparative effectiveness, adherence/persistence) to support access and inform trial design.
• Access Policy and Channel Strategy: Assess policy landscape (Medicare, Medicaid, ACA, IRA/Part D redesign, 340B, state policies), site-of-care and channel dynamics (buy-and-bill, pharmacy benefit, specialty distribution), and implications for design and launch.
• Payer, IDN, and PBM Insights: Plan and synthesize early payer/IDN advisory input and rapid tests (concept reviews, value message testing, coverage criteria simulations) to de-risk access hurdles.
• Competitive and Class Access Analytics:Maintainlandscape of class coverage criteria, step/edit rules,utilizationmanagement, coding/reimbursement precedents;identifyopportunities to differentiate andanticipatebarriers.
• Forecasting & Investment Support: Build access assumptions for early forecasts (gross-to-net, access mix, UM intensity, speed-to-coverage) and partner with Finance onrNPV/scenario analyses for governance.
• Governance and Cross-Functional Leadership: Represent US access in global/US asset teams and at governance gates (indicationsequencing, go/no-go, TPP approval), driving clear, evidence-backed recommendations.
• Compliance and Ethics:Operatewithin US promotional and pre-approval communication standards and company policies; ensure research and external interactions meet compliance requirements.

MinimumQualifications

• Bachelor's degreein health economics, public health, pharmacy, life sciences, business, economics, or a related discipline;advanceddegreesuchasanMPH, MS,PharmD,PhD,orMBA strongly preferred.
• 8+yearsof progressive experienceinthe pharmaceutical, biotechnology, healthcare, payer,orconsultingenvironment,includingsubstantialexperience inUSMarketAccess,HEOR,pricing and reimbursement, orearlyassetstrategy.
• Profiles,clinicaldevelopmentplans,evidencestrategies,andassetinvestmentdecisions.
• DeepunderstandingoftheUSpayerandhealthsystemenvironment,includingcommercialandgovernmentpayers,medicalandpharmacybenefit dynamics, pricing and reimbursement,utilizationmanagement, distribution and site-of-care considerations, and relevant policy trends.
• StrongunderstandingofHEOR,realworldevidence,payerresearch,economicmodeling,andvalueproposition development, with the ability to translate technical analyses into strategic recommendations.
• Demonstratedexperiencerepresentingafunctionormarketperspectiveoncross-functionalasset teams, governance forums, or senior decision-making bodies.
• Proven ability toinfluence senior stakeholders andleadacrossClinical Development,Medical, HEOR,Regulatory,Commercial,Finance, Policy,andglobal market access organizations without direct authority.
• Strongstrategicjudgmentand the abilitytomakeclearrecommendations in conditions of scientific, commercial,andaccessuncertainty.
• Execellent communicationskills,includingthe ability to synthesize complex information, construct a compelling valuenarrative,andinfluenceseniorandglobalstakeholders.
• Demonstratedabilitytomanagemultiple assets,priorities,anddecisiontimelinesina complex, matrixed environment.

Preferred Qualifications

• Advanced degree in health economics, outcomes research, public health, pharmacy, medicine, science, economics, or business.
• Experience spanning more than one relevant discipline, such as Market Access, HEOR, Clinical Development, Medical Affairs, new product planning, pricing, policy, or finance.
• Direct experience supporting early-stage or first-in-class assets from late discovery through Phase 2.
• Experience influencing global asset strategy and translating US access needs into global development and evidence plans.
• Experience contributing to governance decisions involving asset progression,indicationprioritization,evidenceinvestment, licensing, or portfolio prioritization.
• Experience developing innovative pricing, contracting, or value-based access approaches.
• Therapeutic-areaexperience relevant to the assigned pipeline portfolio.
• Experience coaching colleagues or building organizational capability in early market access, HEOR, payer strategy, or value development.

This position is based at our Wilmington, DE campus headquarters for our US Biopharma business.When we put unexpected teams in the same room, we unleash bold thinking with the power to inspire life-changing medicines. In-person working gives us the platform we need to connect, work at pace and challenge perceptions. That's why we work, on average, a minimum of three days per week from the office. But that doesn't mean we're not flexible. We balance the expectation of being in the office while respecting individual flexibility. Join us in our unique and ambitious world.

Date Posted

09-Sept-2026

Closing Date

14-Sept-2026

Our mission is to build an inclusive environment where equal employment opportunities are available to all applicants and employees. In furtherance of that mission, we welcome and consider applications from all qualified candidates, regardless of their protected characteristics. If you have a disability or special need that requires accommodation, please complete the corresponding section in the application form.